AAV1-caspase gene therapy induced pyroptosis for the treatment of tumors
Described herein are compositions and methods for treating, inhibiting, preventing, reducing the severity of and/or reducing the progression of schwannoma, as well as any disease or physiological disease-state in which schwannoma plays a role. The compositions comprise an rAAV vector that includes a caspase-1 gene or a variant thereof and a Schwann cell specific promoter.
1. A recombinant adeno-associated virus (rAAV) vector of serotype AAV1 comprising a caspase-1 gene and a Schwann cell specific promoter.
2. The rAAV vector of claim 1 , wherein the caspase-1 gene is a human, mouse, or rat caspase-1 gene.
3. The rAAV vector of claim 1 , wherein the Schwann cell specific promoter comprises a P0 promoter or a peripheral myelin protein 22 (PMP22) promoter.
4. The rAAV vector of claim 1 , wherein the Schwann cell specific promoter is upstream of the caspase-1 gene.
5. The rAAV vector of claim 1 , further comprising a polyadenylation signal.
6. The rAAV vector of claim 5 , wherein the polyadenylation signal is downstream of the caspase-1 gene.
7. The rAAV vector of claim 5 , wherein the polyadenylation signal comprises a bovine growth hormone polyadenylation signal (BGHpA), a SV40 polyadenylation signal or a rabbit beta-globin polyadenylation signal.
8. The rAAV vector of claim 1 , comprising a sequence as set forth in SEQ ID NO.: 4, or a sequence as set forth in SEQ ID NO.: 5.
9. The rAAV vector of claim 1 , comprising a sequence as set forth in SEQ ID NO.: 6, or a sequence as set forth in SEQ ID NO.: 7.
10. The rAAV vector of claim 1 , wherein the rAAV vector is a polynucleotide.
11. The rAAV vector of claim 1 , wherein the rAAV vector is a single-stranded or double-stranded AAV.
12. The rAAV vector of claim 1 , wherein the rAAV vector is a self-complementary AAV (scAAV).
13. The rAAV vector of claim 5 , further comprising a first AAV inverted terminal repeat (ITR) located upstream of the Schwann cell specific promoter and a second AAV ITR located downstream of the polyadenylation signal.
14. The rAAV vector of claim 13 , wherein the first or second AAV inverted terminal repeat comprises a deletion of the terminal resolution site.
15. The rAAV vector of claim 1 , wherein the rAAV vector is a virus particle.
16. A method of treating, inhibiting, reducing the severity of and/or reducing the progression of a schwanoma related disease-state in a subject, comprising
directly administering a therapeutically effective amount of a composition comprising an rAAV vector of serotype AAV1 comprising a caspase-1 gene and a Schwann cell specific promoter to a schwanoma in the subject, thereby treating, inhibiting, reducing the severity of and/or reducing the progression of the disease-state in the subject.
17. A pharmaceutical composition comprising:
an rAAV vector of serotype AAV1 comprising a caspase-1 gene and a Schwann cell specific promoter; and
a pharmaceutically acceptable carrier.
18. The method of claim 16 , wherein the schwanoma related disease-state is nerve sheath tumor, schwannoma, vestibular schwannoma, sporadic schwannoma, neurofibrosarcoma, neurofibroma, neurofibromatosis (NF), neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), or schwannomatosis, or a combination thereof.
19. The method of claim 16 , wherein administering is intranervously, intracranially, intratumorally, intramuscularly, intravenously, intradermally, or subcutaneously, or a combination thereof.
20. A kit comprising a composition comprising an rAAV vector of serotype AAV1 comprising a caspase-1 gene and a Schwann cell specific promoter contained within packaging materials.